Nanomedicines accessible in the market for clinical interventions

J Control Release. 2021 Feb 10:330:372-397. doi: 10.1016/j.jconrel.2020.12.034. Epub 2020 Dec 25.

Abstract

Nanomedicines refers to nanotechnology inspired pharmaceutical products often referred to as 'nanopharmaceuticals.' It has displayed commendable potential in enhancing therapeutic efficacy as well as in reducing the side effects associated with conventional drug counterpart. Recent years have monitored the entry of a large amount of nanomedicine in the market with an appreciable market share to date. Despite this, the development of nanomedicine is posing challenges (i.e., safety, regulatory hurdles, cost, scale-up issues, etc.) that need to be resolved for their market entry. This review presents a cross-sectional discussion on the nanomedicine-derived products available in the market for both clinical and diagnostic applications. An overview of its market potential, market size, and the products that are currently in the clinical stages is also provided. The review also expounds on the challenges faced by nano-drug products at the time of their commercialization.

Keywords: Clinical trials; Drug delivery; Marketed product; Nanomedicines; Regulatory issues; Scale-up.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cross-Sectional Studies
  • Drug Delivery Systems
  • Nanomedicine*
  • Nanoparticles*
  • Nanotechnology